explore -WSS

explore

author：Wikipedia 2025-10-03 00:39:51 - browse：319

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Cancer diagnosis changes perspective doctor, former hospital CEO

WSS

Beyond aggravation: Constipation is an American epidemic

The Bio Revolution is changing business and society

FDA reorg will put new emphasis on investigations, sources say

Should insurance cover cosmetic surgery?

Weight loss drugs should be covered by insurers, AMA says

Hospitals need to get ahead of regulations on climate change

hotspot

explore

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Unmasking the 'centricity' illusion in clinical trials

Heart attack and stroke risk calculators need revising

Guardant Health colon cancer test endorsed by FDA advisory panel

Tori Bowie and the unacceptable rates of Black maternal death

Type 2 diabetes prevention programs work at large scale: study

Medicare details structure of new drug price negotiation program

FDA reorg will put new emphasis on investigations, sources say

United colonoscopy coverage change 'may cost lives,' doctors say

Medical students need to learn the potent medicine of empathy

focus

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Clinicians often fail to acknowledge the pain caused by long Covid

Study suggests Covid rebound is far more common with Paxlovid than without

Unmasking the 'centricity' illusion in clinical trials

Guardant Health colon cancer test endorsed by FDA advisory panel

Weight loss drugs should be covered by insurers, AMA says

leisure time

explore

focus

knowledge